FDA
-
-
-
-
-
-
-
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
-
-
-
-
-
-
-
PDS Biotech receives patent allowance for PDS0101 cancer therapy
-
-
-
-
-
-
-
PDS Biotechnology raises up to $11.1 million in registered direct offering
-
-
-
-
-
-
-
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
-
-
-
-
-
-
-
PDS Biotechnology (PDSB) Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on PDS Biotechnology Corp (PDSB)
-
-
-
-
-
-
-
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
-
334,461 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


